Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 10, 2014, Pages 1870-1878

  Kawai, Nobuyuki ^a   Lin, Wei ^a,b   Cao, Wei Dong ^b   Ogawa, Daisuke ^a   Miyake, Keisuke ^a   Haba, Reiji ^a   Maeda, Yukito ^a   Yamamoto, Yuka ^a   Nishiyama, Yoshihiro ^a   Tamiya, Takashi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Fluoromisonidazole; Hypoxia; Hypoxia inducible factor 1 (HIF 1); Malignant glioma; Positron emission tomography; Vascular endothelial growth factor (VEGF)

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; VASCULOTROPIN; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; HIF1A PROTEIN, HUMAN; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; ASTROCYTOMA; BODY WEIGHT; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH; TUMOR NECROSIS; VERY ELDERLY; ANALOGS AND DERIVATIVES; BRAIN TUMOR; DIAGNOSTIC USE; GENETICS; GLIOMA; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; FEMALE; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907254721     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2776-9     Document Type: Article

References (35)

1. Hardee ME, Zagzag D. Mechanism of glioma-associated neovascularization. Am J Pathol. 2012;181:1126–41.
2. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 2005;7:134–53.
3. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009;92:317–35.
4. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13.
5. Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J Neurooncol. 2006;78:281–93.
6. Argyriou AA, Giannopoulou E, Kalofonos HP. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology. 2009;77:1–11.
7. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–26.
8. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133–7.
9. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HLP, Muzi M, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50:36–44.
10. Kawai N, Maeda Y, Kudomi N, Miyake K, Okada M, Yamamoto Y, et al. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2011;38:441–50.
11. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868–73.
12. Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99:217–25.
13. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410–8.
14. Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30.
15. de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep. 2014;16:380. doi:10.1007/s11912-014-0380-6.
16. Yamamoto Y, Maeda Y, Kawai N, Kudomi N, Aga F, Ono Y, et al. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl Med Commun. 2012;33:621–5.
17. Oh SJ, Chi DY, Mosdzianowski C, Kim JY, Gil HS, Kang SH, et al. Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module. Nucl Med Biol. 2005;32:899–905.
18. Cao L, Cao W, Zhang W, Lin H, Yang X, Zhen H, et al. Identification of 14-3-3 protein isoforms in human astrocytoma by immunohistochemistry. Neurosci Lett. 2008;432:94–9.
19. Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39:760–70.
20. Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM, Kavantzas N, Boviatsis E, et al. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol. 2004;30:267–78.
21. Mashiko R, Takano S, Ishikawa E, Yamamoto T, Nakai K, Matsumura A. Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol. 2011;102:43–50.
22. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113:1032–42.
23. Chaudhry IH, O’Donovan DG, Brenchley PEC, Reid H, Roberts ISD. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology. 2001;39:409–15.
24. Miyagami M, Katayama Y. Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med Mol Morphol. 2005;38:36–42.
25. Khasraw M, Simeonovic M, Grommes C. Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther. 2012;12:1101–11.
26. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142–8.
27. Déry MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol. 2005;37:535–40.
28. Cárdenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res. 2008;68:5812–9.
29. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res. 2009;172:653–65.
30. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15:1312–4.
31. Berra E, Richard DE, Gothié E, Pouysségur J. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett. 2001;491:85–90.
32. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445–53.
33. Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, Ladekarl M, Havsteen H, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol. 2003;67:35–44.
34. Bentzen L, Keiding S, Nordsmark M, Falborg L, Hansen SB, Keller J, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol. 2003;67:339–44.
35. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol. 2005;50:2209–24.